Entity Central Index Key Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Operating leases imputed interest. Cover [Abstract] Document Information [Table] Document Information [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Class A Common Stock [Member] Common Class A [Member] Class B Common Stock [Member] Common Class B [Member] Document Information [Line Items] Document Information [Line Items] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Shell Company Entity Shell Company Entity Address, Postal Zip Code Entity Address Postal Zip Code Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name City Area Code City Area Code Local Phone Number Local Phone Number Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Current deposits Deposits Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use assets Operating Lease Right Of Use Asset Long-term investments Long Term Investments Total assets Assets Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable and accrued expenses Accounts Payable And Accrued Liabilities Current Current portion of operating lease liabilities Operating Lease Liability Current Current portion of contract liabilities Contract With Customer Liability Current Current portion of notes payable Notes Payable Current Total current liabilities Liabilities Current Operating lease liabilities, net of current portion Operating Lease Liability Noncurrent Warrant liability, related party Due To Related Parties Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Redeemable noncontrolling interest Redeemable Noncontrolling Interest Equity Carrying Amount Stockholders’ deficit: Stockholders Equity [Abstract] Common stock value Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ deficit attributable to vTv Therapeutics Inc. Stockholders Equity Total liabilities, redeemable noncontrolling interest and stockholders’ deficit Liabilities And Stockholders Equity Common stock par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares outstanding Common Stock Shares Outstanding The net amount of other related party income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. Income Statement [Abstract] Revenue Revenue From Contract With Customer Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Operating loss Operating Income Loss Other expense Other Nonoperating Income Expense Other income (expense) – related party Other Income Expenses Related Party Interest income Investment Income Interest Interest expense Interest Expense Loss before income taxes and noncontrolling interest Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax provision Income Tax Expense Benefit Net loss before noncontrolling interest Profit Loss Less: net loss attributable to noncontrolling interest Net Income Loss Attributable To Noncontrolling Interest Net loss attributable to vTv Therapeutics Inc. Net Income Loss Net loss attributable to vTv Therapeutics Inc. common shareholders Net Income Loss Available To Common Stockholders Basic Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted Earnings Per Share Basic And Diluted Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Issuance of Class A Common Stock under LPC agreement. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Noncontrolling Interest [Member] Noncontrolling Interest [Member] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Redeemable noncontrolling interests. Redeemable Noncontrolling Interest [Member] Redeemable Noncontrolling Interests [Member] Beginning balance Beginning balance, redeemable noncontrolling interest Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests Beginning balance, shares Net loss Share-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Exchange of Class B Common Stock for Class A Common Stock Stock Issued During Period Value Conversion Of Convertible Securities Exchange of Class B Common Stock for Class A Common Stock, shares Stock Issued During Period Shares Conversion Of Convertible Securities Exercise of stock options Stock Issued During Period Value Stock Options Exercised Exercise of stock options, shares Stock Issued During Period Shares Stock Options Exercised Issuance of Class A Common Stock under LPC Agreement Issuance Of Class A Common Stock Under L P C Agreement Issuance of Class A Common Stock under LPC agreement shares.. Issuance of Class A Common Stock under LPC Agreement, shares Issuance Of Class A Common Stock Under L P C Agreement Shares Change in redemption value of noncontrolling interest Minority Interest Change In Redemption Value Ending balance Ending balance, redeemable noncontrolling interest Ending balance, shares Change in fair value of warrants related party. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss before noncontrolling interest Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation expense Depreciation Share-based compensation expense Share Based Compensation Change in fair value of investments Unrealized Gain Loss On Investments Change in fair value of warrants, related party Change In Fair Value Of Warrants Related Party Changes in assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable and accrued expenses Increase Decrease In Accounts Payable And Accrued Liabilities Contract liabilities Increase Decrease In Contract With Customer Liability Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of Class A Common Stock, net of offering costs Proceeds From Issuance Of Common Stock Proceeds from exercise of stock options Proceeds From Stock Options Exercised Repayment of notes payable Repayments Of Notes Payable Net cash (used in) provided by financing activities Net Cash Provided By Used In Financing Activities Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Total cash, cash equivalents and restricted cash and cash equivalents, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Total cash, cash equivalents and restricted cash and cash equivalents, end of period Non-cash activities: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Accounting Policies [Abstract] Description of Business, Basis of Presentation and Going Concern Business Description And Basis Of Presentation [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Share-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Investments Debt And Equity Securities [Abstract] Investments Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Leases [Abstract] Leases Lessee Operating Leases [Text Block] Noncontrolling Interest [Abstract] Redeemable Noncontrolling Interest Minority Interest Disclosure [Text Block] Equity [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Related Party Transactions [Abstract] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss per Share Earnings Per Share [Text Block] Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Unaudited interim financial information policy. Unaudited Interim Financial Information Unaudited Interim Financial Information Policy [Text Block] Use of Estimates Use Of Estimates Concentration of Credit Risk Concentration Risk Credit Risk Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Investments Investment Policy [Text Block] Revenue Recognition Revenue From Contract With Customer Policy [Text Block] Research and Development Research And Development Expense Policy Recently Issued Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Summary of Contract Liabilities Related to Company's Collaboration Agreements Contract With Customer Asset And Liability Table [Text Block] Summary of Stock Award Activity for the Period Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Compensation Expense Related to Grants of Stock Options Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Tabular disclosure of investment in equity security with and without readily determinable fair value. Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed Equity Securities With And Without Readily Determinable Fair Value Table [Text Block] Schedule of Maturities of Lease Liabilities for Operating Leases Lessee Operating Lease Liability Maturity Table [Text Block] Summary of Net Income Attributable to Vtv Therapeutics Inc Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Effects Of Changes Net [Text Block] Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Summarizes the Conclusions Reached Regarding Fair Value Measurements Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Significant Inputs Utilized in the Valuation of Letter Agreement Warrants Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block] Percentage of non voting economic interest. Percentage of non voting economic interest by parent. Variable Interests And Equity Method Investments Disclosure [Abstract] Variable Interests And Equity Method Investments Disclosure [Abstract] Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Legal Entity Legal Entity [Axis] Entity Entity [Domain] vTv LLC. vTv Therapeutics LLC [Member] V Tv L L C [Member] License agreement obligations. License Agreement Obligations License Agreement Obligations [Axis] License agreement obligations. License Agreement Obligations License Agreement Obligations [Domain] LPC purchase agreement. LPC Purchase Agreement [Member] L P C Purchase Agreement [Member] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Cantor fitzgerald member. Cantor Fitzgerald [Member] Cantor Fitzgerald [Member] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC Percentage Of Non Voting Economic Interest Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC Percentage Of Non Voting Economic Interest By Parent Remaining availability under our controlled equity offering sales agreement Common Stock, Capital Shares Reserved for Future Issuance Common Stock Capital Shares Reserved For Future Issuance Remaining available stock value Remaining Availability Stock Issued During Period Value New Issues Number of customers. Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenue [Member] Sales Revenue Net [Member] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer [Member] Customer Concentration Risk [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Concentration risk percentage Concentration Risk Percentage1 Number of customers Number Of Customers Adjustments to transaction price for performance obligations. Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Collaborative Arrangements [Member] Collaborative Arrangement [Member] Reneo Pharmaceuticals Inc. Reneo [Member] Reneo Pharmaceuticals Inc [Member] Hangzhou Zhongmei Huadong Pharmaceutical Company Limited. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member] Other Commitments Other Commitments [Axis] Other Commitments Other Commitments [Domain] Phase two multi-regional clinical trial. Phase 2 MRCT [Member] Phase Two Multi Regional Clinical Trial [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] License and technology transfer services of chemistry and manufacturing know-how. License and Technology Transfer Services of Chemistry and Manufacturing Know-How [Member] License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member] Joint development committee. Joint Development Committee [Member] Joint Development Committee [Member] Newsoara Biopharma Co Ltd. Newsoara Biopharma Co Ltd [Member] Newsoara Biopharma Co Ltd [Member] License and technology transfer services. License And Technology Transfer Services [Member] License And Technology Transfer Services [Member] Anteris Bio, Inc. Anteris Bio, Inc. [Member] Anteris Bio Inc [Member] JDRF international. JDRF [Member] J D R F International [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaboration revenue recognized Contract With Customer Liability Revenue Recognized Adjustments to transaction price for performance obligations Adjustments To Transaction Price For Performance Obligations Maximum sponsoring contribution amount. Potential development and regulatory milestone payments receivable. Maximum contribution amount to clinical trial Maximum Sponsoring Contribution Amount Potential development and regulatory milestone payments Potential Development And Regulatory Milestone Payments Receivable Unrecognized amount of transaction price allocated to performance obligation Revenue Remaining Performance Obligation Revenue recognized from change in estimated transaction prices Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price License fee received. License fee received License Fee Received Equity interest received Proceeds From Interest And Dividends Received Maximum research funding receivable based on achievement of research and development milestones. Maximum funding percentage of research and development milestones. Maximum research funding receivable achievement based on research and development milestones Maximum Research Funding Receivable Based On Achievement Of Research And Development Milestones Maximum funding percentage of research and development milestones Maximum Funding Percentage Of Research And Development Milestones Funding received. Funding received Funding Received Deferred Revenue Disclosure [Abstract] Current portion of contract liabilities Total contract liabilities Contract With Customer Liability Share Based Compensation [Abstract] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock Option [Member] Employee Stock Option [Member] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Strategic advisor. Strategic Advisor [Member] Strategic Advisor [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Non-qualified stock option awards vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Non-qualified stock option awards expiration term Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Unrecognized compensation cost related to non-vested share-based compensation arrangements Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Weighted average period to recognize unrecognized share-based compensation cost Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Weighted average grant date fair value of options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled. Outstanding stock options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Stock options cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Share Based Arrangements To Obtain Goods And Services [Abstract] Number of Shares, Awards outstanding, Beginning balance Number of Shares, Granted Number of Shares, Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Number of Shares, Awards outstanding, Ending balance Number of Shares, Options exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Number of Shares, Options exercisable, Weighted average remaining contractual term Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Number of Shares, Options vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number Number of Shares, Options vested and expected to vest, Weighted average remaining contractual term Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 Weighted-Average Exercise Price, Awards outstanding, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted-Average Exercise Price, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Awards outstanding, Ending balance Weighted-Average Exercise Price, Options exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Weighted-Average Exercise Price, Options vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development [Member] Research And Development Expense [Member] General and Administrative [Member] General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total share-based compensation expense Allocated Share Based Compensation Expense Investment ownership percentage. Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Equity method investments, ownership percentage Investment Ownership Percentage Equity investments with readily determinable fair value. Equity Securities Without Readily Determinable Fair Value [Table] Equity Securities Without Readily Determinable Fair Value [Table] Preferred Stock [Member] Preferred Stock [Member] Equity Securities Without Readily Determinable Fair Value [Line Items] Equity Securities Without Readily Determinable Fair Value [Line Items] Equity Investments with Readily Determinable Fair Value, Amount Equity Investments With Readily Determinable Fair Value Equity Securities without Readily Determinable Fair Value, Amount Equity Securities Without Readily Determinable Fair Value Amount Change in fair value of investments Potential milestone payment. Commitments and Contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Developmental and regulatory milestone payment. Developmental and Regulatory Milestone Payment [Member] Developmental And Regulatory Milestone Payment [Member] Sales-based milestones payment. Sales-based Milestones Payment [Member] Sales Based Milestones Payment [Member] Satisfaction of milestone payment. Satisfaction of Milestone Payment [Member] Satisfaction Of Milestone Payment [Member] Novo license agreement. Novo License Agreement [Member] Novo License Agreement [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] Other indication. Other Indication [Member] Other Indication [Member] Type 1 diabetes. Type 1 Diabetes [Member] Type One Diabetes [Member] Type 2 diabetes. Type 2 Diabetes [Member] Type Two Diabetes [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Potential milestone payment Potential Milestone Payment Weighted average incremental borrowing rate Operating Lease Weighted Average Discount Rate Percent Remaining operating lease term Operating Lease Weighted Average Remaining Lease Term1 Operating Lease Liabilities Payments Due [Abstract] 2022 (remaining nine months) Lessee Operating Lease Liability Payments Remainder Of Fiscal Year 2023 Lessee Operating Lease Liability Payments Due Next Twelve Months 2024 Lessee Operating Lease Liability Payments Due Year Two 2025 Lessee Operating Lease Liability Payments Due Year Three 2026 Lessee Operating Lease Liability Payments Due Year Four Thereafter Lessee Operating Lease Liability Payments Due After Year Four Total lease payments Lessee Operating Lease Liability Payments Due Less: imputed interest Operating Leases Imputed Interest Present value of lease liabilities Operating Lease Liability Period used to determine exchange value based on weighted average price of Class A common stock. Redeemable non controlling interest exchange agreement stock conversion ratio. Minority Interest [Table] Minority Interest [Table] Stock Conversion Description Conversion Of Stock By Unique Description [Axis] Conversion of Stock, Name Conversion Of Stock Name [Domain] Exchange of redeemable non controlling interest to class A common stock. Exchange of Redeemable Non controlling Interest To Class A Common Stock [Member] Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member] Noncontrolling Interest [Line Items] Minority Interest [Line Items] Noncontrolling interest ownership percentage Number of days used to determine exchange value based on weighted average price of Class A common stock Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock Stock conversion ratio Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio Redeemable noncontrolling interest temporary equity redemption value. Redemption amount of noncontrolling interest Redeemable Noncontrolling Interest Temporary Equity Redemption Value Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent. Net loss attributable to vTv Therapeutics Inc. common shareholders Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of LLC Units as a result of common stock issuances Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net Increase in common stock shares authorized. Common stock and preferred stock shares authorized. Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Transaction Type Transaction Type [Axis] Transaction Transaction [Domain] At the market offering. ATM Offering [Member] At The Market Offering [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Increase in shares authorized Increase In Common Stock Shares Authorized Capital stock, shares authorized Common Stock And Preferred Stock Shares Authorized Aggregate offering price of shares. Public float. Aggregate offering price Stock Issued During Period Value New Issues Aggregate offering price Aggregate Offering Price Of Shares Shares sold Sale Of Stock Number Of Shares Issued In Transaction Public float Public Float Net proceeds from issuance of common stock Ownership percentage of majority owner. Commitment, Contingency And Related Party Transactions [Abstract] Commitment Contingency And Related Party Transactions [Abstract] Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] MacAndrews and Forbes Incorporated. MacAndrews & Forbes Incorporated [Member] Mac Andrews And Forbes Incorporated [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Shares held by related party Investments In And Advances To Affiliates Balance Shares Ownership percentage of majority owner Ownership Percentage Of Majority Owner Percentage of amount of cash savings. Description of tax receivable agreement. Amount of cash savings percentage Percentage Of Amount Of Cash Savings Description of tax receivable agreement Tax Receivable Agreement Description Income taxes. Income taxes. Income Taxes [Table] Income Taxes [Table] M&F TTP Holdings LLC. M&F TTP Holdings LLC [Member] M F T T P Holdings L L C [Member] Income Taxes [Line Items] Income Taxes [Line Items] US statutory corporate income tax rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Net income loss available to common stockholders basic and diluted. Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Numerator: Net Income Loss [Abstract] Net loss Less: Net loss attributable to noncontrolling interests Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted Net Income Loss Available To Common Stockholders Basic And Diluted Denominator: Weighted Average Number Of Shares Outstanding [Abstract] Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Common Stock Options Granted Under the Plan [Member] Common Stock Warrants [Member] Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Potentially dilutive securities not included in calculation of dilutive net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Fair value of assets and liabilities measured on recurring basis. Fair value of assets and liabilities measured on recurring basis table. Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value Measurements Recurring [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Quoted Prices in Active Markets for Identical Asset (Level 1) [Member] Fair Value Inputs Level1 [Member] Significant Other Observable Inputs (Level 2) [Member] Fair Value Inputs Level2 [Member] Significant Unobservable Inputs (Level 3) [Member] Fair Value Inputs Level3 [Member] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Warrant liability, related party. Warrant Liability, Related Party [Member] Warrant Liability Related Party [Member] Equity Securities With Readily Determinable Fair Value [Member] Equity Securities [Member] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Total Assets Fair Value Disclosure Total Liabilities Fair Value Disclosure Fair value measurement with unobservable inputs reconciliation recurring basis warrant liability issuance. Fair value measurement with unobservable inputs reconciliation recurring basis warrant liability sales. Balance at January 1 Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Net Change in fair value included in earnings Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings Purchases / Issuance Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Warrant Liability Issuance Sales / Repurchases Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Warrant Liability Sales Balance at March 31, Fair value equity transfers in and out of level 3 instruments Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net Fair value equity transfers between level 1 and level 2 instruments Fair Value Equity Level1 To Level2 Transfers Amount Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Letter agreement warrants. Letter Agreement Warrants [Member] Letter Agreement Warrants [Member] Weighted Average [Member] Weighted Average [Member] Measurement Input Type Measurement Input Type [Axis] Measurement Input Type Measurement Input Type [Domain] Expected Volatility [Member] Measurement Input Price Volatility [Member] Risk-Free Interest Rate [Member] Measurement Input Risk Free Interest Rate [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Inputs utilized in the valuation of warrants Warrants And Rights Outstanding Measurement Input